Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Aug 31:11:2050313X231195961.
doi: 10.1177/2050313X231195961. eCollection 2023.

Clozapine-induced eosinophilia: A case report

Affiliations
Case Reports

Clozapine-induced eosinophilia: A case report

Soumitra Das et al. SAGE Open Med Case Rep. .

Abstract

Schizophrenia is a chronic neuropsychiatric illness defined by the appearance of positive, and negative symptoms and/or cognitive impairment. Antipsychotic drugs are predominantly used in the treatment of psychotic disorders, but not all patients with schizophrenia respond to every antipsychotic medication. Clozapine is one of the best atypical antipsychotics and is highly effective in treating treatment-resistant schizophrenia. Evidence suggests that clozapine appears to be effective in lowering the risk of suicide, extrapyramidal side effects, and relapse in patients with schizophrenia. Per contra, clozapine is not the first-line treatment due to its unalterable aftereffects such as agranulocytosis, metabolic syndrome, seizures, and rarely, eosinophilia. Eosinophilia can be life-threatening. Eosinophils infiltrate different tissues and cause inflammation in multiple organs causing end-organ damage. The current study aimed to report the incidence of eosinophilia associated with clozapine use in patients with schizophrenia. Literature on clozapine-induced eosinophilia is relatively scarce. Understanding the progression and management of clozapine-induced eosinophilia and its end-organ effects is imperative. While there is insufficient data about the guidelines in the management of clozapine-induced eosinophilia, this study contributes to understanding the patterns of the disease progression with clozapine dosage. A case study was done on a patient with schizophrenia and autistic spectrum disorder who was on clozapine. Data on how eosinophil levels varied with clozapine dosing was analyzed and documented. The evidence of clozapine dosage affecting eosinophil and C-reactive protein levels in this patient was summarized in a table and a narrative review.

Keywords: Clozapine; antipsychotics; case report; eosinophilia.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Timeline of clozapine-induced eosinophilia.
Figure 2.
Figure 2.
Timeline of clozapine-induced eosinophilia (Graphical representation).

Similar articles

References

    1. Ayano G, Tesfaw G, Shumet S. The prevalence of schizophrenia and other psychotic disorders among homeless people: a systematic review and meta-analysis. BMC Psychiatry 2019; 19: 370. - PMC - PubMed
    1. Kane JM, Agid O, Baldwin ML, et al.. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry 2019; 80(2): 2783. - PubMed
    1. Chakrabarti S. Clozapine resistant schizophrenia: newer avenues of management. World J Psychiatry 2021; 11(8): 429–448. - PMC - PubMed
    1. Daniel P, Rajaree KM, Rudy L, et al.. Myocarditis in patients on long-term antipsychotics—mechanism, management, and recent updates. Heliyon 2023; 9: e13930. - PMC - PubMed
    1. Datta T, Solomon AJ. Clozapine-induced myocarditis. Oxf Med Case Reports 2018; 2018(1): omx080. - PMC - PubMed

Publication types